Six Signs You May Have Gastroparesis

April 18th, 2011

stomach
Gastroparesis sounds like a long and scary word. In laymen's terms, it's a disorder in which the stomach takes too long to empty its contents. Normally, the stomach contracts to move food down into the small intestine for digestion, using the vagus nerve, which controls the movement of food from the stomach through the digestive tract.

Gastroparesis happens when the vagus nerve is damaged, and the muscles of the stomach and intestines do not work normally. Food then moves slowly or stops moving through the digestive tract. So, if your stomach has been feeling sluggish, read on for some common gastroparesis symptoms.

Are you diabetic? It doesn't seem fair to add yet another ailment to your list when you're already dealing with diabetes, but unfortunately the most common cause of gastroparesis is diabetes. Why? People with diabetes have high blood glucose, or blood sugar, which in turn causes chemical changes in nerves, and damages the blood vessels that carry oxygen and nutrients to the nerves. Over time, high blood glucose can damage the vagus nerve.

  • Do you have heartburn or pain in your upper abdomen?
  • Are you nauseous after eating a meal?
  • Do you vomit up undigested food—sometimes several hours after a meal?

  • Do you have an early feeling of fullness after only a few bites of food?

These are all signs you may have gastroparesis, as if the meal you've just devoured is at a stomach standstill, it can easily come back up.

  • Are you experiencing unexpected weight loss?This could be due to poor absorption of nutrients or low calorie intake, common side affects of gastroparesis.

  • Other common symptoms to take note of are abdominal bloating, a lack of appetite and gastroesophageal reflux.

Keep in mind that the symptoms of gastroparesis may be mild or severe, depending on the person. Many people with gastroparesis experience a wide range of symptoms, which makes the disorder difficult for the physician to diagnose. If you're experiencing any of the above symptoms, the best strategy is to keep a food diary with a detailed list of symptoms that arise after certain meals have been ingested. Once you have some documentation to show your doctor, schedule an appointment.

As far as easing of suffering goes, the treatment of gastroparesis depends on the severity of the symptoms. Treatment helps you manage the condition so you can be as healthy and comfortable as possible, as in most cases, treatment does not cure gastroparesis.

A common medication prescribed in many countries for gastroparesis is prescription medication Motilium, or its cheaper form, generic domperidone. The FDA has not approved prescription domperidone for sale in the US, but you can buy prescription domperidone online through a licensed online Canadian pharmacy with a valid doctor's prescription. With any health uncertainties, the key to finding answers is to listen to your body and then report your findings to a trusted doctor.

Dating with Diabetes-Related Erectile Dysfunction

May 12th, 2011

According to the National Institutes of Health, having diabetes more than doubles the risk of a man experiencing erectile dysfunction, or ED. Between 20 and 75% of men with diabetes experience ED, compared to about one in every five men without a chronic health condition. That's because diabetes can cause nerve and artery damage that can make achieving an erection difficult.

ED is a much more common occurrence in the general population than most people realize. ED can be caused by a variety of physical and psychological factors, including stress, low self esteem, disease, surgery, injury, and tobacco, drug and alcohol use. There are over 200 medications that can cause or contribute to ED. Diabetes medications are not among them.

Almost all men will experience ED at some point in their life, especially as they get older. There are now a number of effective treatments for ED, including lifestyle changes, prescription medication, and injections, pumps and pellets. Viagra and similar ED medication are among the top-selling prescription drugs in modern pharmaceutical history.

Impotence is a particular issue for single men who want to date. About.com guide Cory Silverberg posted a straightforward and reassuring article about the challenges of dating for single men with ED. To read Silverberg's article >CLICK HERE.<

Gene Discovery Has Great Potential in Diabetes Control

May 17th, 2011

Could the discovery of a "master regulator" gene that controls the activity of other genes linked to diabetes, obesity and heart disease lead to a treatment to address all three conditions at once?

A groundbreaking major study has great therapeutic potential in treating not only diabetes, but also the equally serious and widespread conditions obesity and heart disease. A team of researchers led by the University of Oxford and King's College London in Britain have found a "master regulator" gene in fat tissue that controls the activity of other genes in body fat.

The gene, called the KLF14 gene, had already been linked to both type 2 diabetes and cholesterol levels, but the role it played was unknown. The research team examined over 20,000 genes from biopsies of the subcutaneous fat of 800 UK female twin volunteers and, later, an additional 600 Icelandic volunteers. They discovered an unexpected interconnectedness between the KLF14 gene and other genes found in fat that are linked to metabolic traits such as obesity, cholesterol, and glucose and insulin levels.

Excess body fat plays a major role in the development of metabolic disorders (disorders involving an alteration in the normal metabolism of lipids, carbohydrates, proteins, water and nucleic acids) including diabetes and heart disease. As metabolic conditions are closely related, many patients suffer from a combination of conditions such as obesity and diabetes, or heart disease and diabetes.

In fact, adults with diabetes are 2 to 4 times more likely to develop heart disease or suffer a stroke than those without diabetes, and about 65% of diabetics die from one or the other. Obesity is believed to be the biggest cause of insulin resistance. Obesity and diabetes are so interconnected that the current concurrent explosion of both has been dubbed the "diabesity epidemic". The prospect of a treatment that would address diabetes, heart disease and obesity together is more than a little heartening.

University of Oxford Professor Mark McCarthy was the study's co-leader. "KLF14 seems to act as a master switch controlling processes that connect changes in the behavior of subcutaneous fat to disturbances in muscle and liver that contribute to diabetes and other conditions," McCarthy explains, "We are working hard right now to understand these processes and how we can use this information to improve treatment of these conditions."

Professor Tim Spector also co-led the study, dubbed the MuTHER Project. "This is the first major study that shows how small changes in one master regulator gene can cause a cascade of other metabolic effects in other genes," says Spector, "This has great therapeutic potential, especially as by studying large detailed populations such as twins, we hope to find more of these regulators."

Nicotine Raises Blood Sugar

June 22nd, 2011

The Department of Chemistry at California State Polytechnic University has some important news about smoking and blood sugar levels, especially for diabetics:

  • Nicotine is now known to raise blood sugar levels.
  • The more you smoke, the higher your blood sugar rises.
  • In laboratory testing, two days of nicotine dosing (the equivalent of one or two packs a day) increased HbA1c levels (average blood sugar readings over a period of time) in blood samples by up to 34.5 percent.
  • An increase in HbA1c levels of just 1 percent equals a 40 percent increase in the risk of diabetes complications.
  • Nicotine replacement products such as gum and patches have the same effect on blood sugar as smoking.

Increases in blood sugar and poor diabetes control have already been clearly linked to diabetes complications such as heart attack and stroke, eye and kidney disease and nerve damage, and it was known that diabetics who smoke have higher levels of complications than diabetics who don't smoke.

What wasn't clear was which of the thousands of chemicals in cigarettes were responsible. It's now believed that nicotine may impact glucose metabolism by interfering with the way glucose attaches to proteins, possibly changing their structure and function.

The American Cancer Society has developed a useful guide to help both diabetics and non-diabetics quit smoking. Download the PDF >HERE<.

Dramatic Increase in Life Expectancy for Type 1 Diabetics

June 27th, 2011

ScienceDaily (2011-06-25) -- The life expectancy of people diagnosed with Type 1 diabetes between 1965 and 1980 dramatically increased, compared to people diagnosed with Type 1 diabetes between 1950 and 1964, according to a new study. ... > http://www.sciencedaily.com/releases/2011/06/110624182309.htm read full article

Thirty Seven Strawberries a Day Keep the Doctor Away

July 5th, 2011

A flavonoid called fisetin, found in abundance in strawberries, has been found to lessen complications of diabetes in mice. Fisetin is a neuroprotective flavonoid that can target multiple organs, suggesting that a single natural remedy could be developed to address numerous diabetes complications.

But obtaining a protective patent to bring a natural product like fisetin to market is difficult, meaning further research is stalled until researchers can find someone willing to support a clinical trial. Read more about the benefits of strawberries and the recent research on fisetin and diabetic complications on Diabetic Live.

Researchers Invent New Drug Delivery Device to Treat Diabetes-Related Vision Loss

July 6th, 2011

ScienceDaily (2011-06-29) -- Engineers and scientists have developed a device that can be implanted behind the eye for controlled and on-demand release of drugs to treat retinal damage caused by diabetes. Diabetic retinopathy is the leading cause of vision loss among patients with diabetes. The disease is caused by the unwanted growth of capillary cells in the retina, which in its advanced stages can result in blindness.

The novel drug delivery mechanism is detailed in the current issue of Lab on a Chip, a multidisciplinary journal on innovative microfluidic and nanofluidic technologies.

Read the full article...

Diabetes and Gastroparesis: A Vicious Cycle

July 18th, 2011

Diabetes is the most common cause of gastroparesis, or delayed stomach emptying. That's because years of high blood glucose damage the vagus nerve, which controls the movement of food from the stomach through the digestive tract. Both type 1 and type 2 diabetics are at risk of gastroparesis.

When the vagus nerve is damaged, food either moves too slowly through the digestive system, or doesn't move at all. As a result, people with gastroparesis often feel bloated, feel full after eating a small amount, and may experience heartburn, stomach and abdominal pain, nausea and vomiting, loss of appetite, and acid reflux.

Gastroparesis is a vicious cycle for a diabetic. Not only does uncontrolled blood sugar lead to gastroparesis, gastroparesis leads to poor blood sugar control due to the irregular passage of food through the digestive system. When food is finally absorbed, blood sugar levels may rise unexpectedly.

Diabetics with gastroparesis must check their blood glucose regularly. They may need to adjust their insulin therapy by changing their insulin dose, the type of insulin they take, or the time of day they take it.

Gastroparesis Diagnosis

Gastroparesis can be difficult to diagnose because of the wide range of both type and severity of symptoms. The condition is usually confirmed with stomach x-rays, a manometer (a device that measures pressure and muscle movements), and gastric emptying scans.

Until recently, those undergoing gastric emptying scans were given egg meal mixed with a radioactive isotope to allow tracking of the stomach contents using radioactivity detectors - a process called radiolabeling. This posed a problem for those patients who were allergic to eggs, or couldn't eat them for religious or lifestyle reasons.

Recently, nuclear medicine researchers discovered a way to incorporate the isotopes into instant oatmeal instead of egg meal. Radiolabeling using both regular and gluten free oatmeal proved just as effective for the molecular imaging of gastric emptying as the tests using standard egg meal.

Gastroparesis Treatment

Gastroparesis is almost always a chronic condition. It can be treated, but rarely cured. There are two main treatment goals for diabetics with gastroparesis - to improve stomach emptying, and to control blood sugar levels.

Patients are advised to avoid high fat and high fiber foods, to eat frequent small meals for easier digestion, and in some cases to eat only pureed or liquid meals until their symptoms improve.

If dietary changes alone don't help, the next line of treatment in the US is usually prescription metoclopramide to treat nausea and vomiting, and to facilitate gastric emptying. Due to the risk of side effects including drowsiness, dizziness, weakness and irreversible movement disorders, it is only approved for short-term treatment. The risk of developing a permanent movement disorder (tardive dyskinesia) is higher for people with diabetes.

Less frequently, the antibiotic erythromycin is prescribed to speed up stomach emptying. Like metoclopramide, it can have serious side effects, and can worsen symptoms like nausea.

Prescription domperidone (Motilium) is the preferred treatment in most countries, and has been for many years. Domperidone both aids gastric emptying and eases gastroparesis symptoms. Side effects of domperidone are less serious, and tend to disappear as the body adjusts to the medication.

But, despite numerous US clinical trials that established its safety and effectiveness, and the fact its own division of gastrointestinal drugs approved the use of domperidone, the FDA has still not given domperidone for gastroparesis the green light.

However, the FDA is encouraging doctors who would like to prescribe domperidone to patients with severe gastrointestinal disorders to make an Investigational New Drug application, which would allow them to purchase domperidone and administer it to their patients.

In the meantime, the fight for domperidone FDA approval continues. The Gastroparesis Patient Association is circulating an online petition to urge the FDA to review its decision on domperidone medication.

Researcher Links Diabetic Complication to Nerve Damage in Bone Marrow

August 5th, 2011

?ScienceDaily (2010-01-08) -- Scientists have discovered a link between diabetes and bone marrow nerve damage that may help treat one of the most common and potentially blindness-causing diabetes complications - diabetic retinopathy.

The key to better treating retinopathy - damage to blood vessels in the retina that affects up to 80 percent of diabetic patients - lies not in the retina but in damage to the nerves found in bone marrow that leads to the abnormal release of stem cells, said Julia Busik, an associate professor in MSU's Department of Physiology.

> read full article

New Treatment Approach for Diabetic Macular Edema

August 23rd, 2011

SOUTHAMPTON, England, August 23, 2011 /PRNewswire

KalVista Pharmaceuticals ("KalVista"), a new ophthalmology company with a focus on diabetic macular edema (DME), has raised £8 million in a series A round from leading life sciences investors Novo A/S and SV Life Sciences. The company is developing novel, small molecule plasma kallikrein inhibitors, which represent a new approach to the treatment of DME, a leading cause of adult visual loss in developed countries and a major unmet medical need. KalVista's advanced pre-clinical product pipeline is targeting both intravitreal injection and oral administration routes. KalVista acquired these inhibitors plus all relevant intellectual property from Vantia Therapeutics.

KalVista's scientific founders include world-leading experts in ophthalmology, diabetes and diabetes-related complications, Dr Lloyd Paul Aiello and Dr Edward P. Feener. Dr Aiello is Professor of Ophthalmology at Harvard Medical School, Director of the Joslin's Beetham Eye Institute and Inaugural Chair of the National Eye Institute Diabetic Retinopathy Clinical Research Network.

Dr Feener is Associate Professor of Medicine at Harvard Medical School and an Investigator in Vascular Cell Biology at the Joslin Diabetes Center, where his team led the discovery of plasma kallikrein in the vitreous fluid from people with DME and has shown that inhibition of plasma kallikrein decreases pathological retinal vascular permeability in pre-clinical studies. Dr Aiello has guided the clinical development programs for a wide range of recent ophthalmology drugs, and has been a lead investigator in the trials determining the benefit of VEGF (vascular endothelial growth factor) inhibitors for the treatment of DME.

Plasma kallikrein is a circulating serine protease that represents an attractive drug target as it is believed to be central to the pathogenesis of DME within the diseased retina, but is not essential for normal function. The detrimental effects of plasma kallikrein on the retina occur independently of VEGF, which has been an area of intense recent interest as a target for treating DME.

However, while intravitreal VEGF inhibitors have shown clear benefit in clinical trials through reducing macular edema and increasing visual acuity, a large proportion of DME patients do not respond fully to VEGF treatment. KalVista's approach targeting plasma kallikrein inhibition therefore has the potential to add to the treatment options for sufferers of DME including those that are non-responsive to VEGF inhibitors.

KalVista is supporting the therapeutic expertise with a management team with proven experience in bringing small molecules from discovery through the clinic to commercialisation. This team is led by Andrew Crockett as CEO and includes the former discovery group from Vantia Therapeutics. This group developed the extensive library of proprietary plasma kallikrein inhibitors, including the lead compounds that now form the basis of KalVista's discovery platform.

The KalVista board of directors will include Graham Boulnois of SV Life Sciences as Chairman, Martin Edwards of Novo A/S as Non-executive Director and Andrew Crockett as CEO.

Dr Lloyd Paul Aiello, Director of Joslin's Beetham Eye Institute and Co-founder of KalVista, commented on today's announcement: "Diabetic macular edema remains one of the major challenges in ophthalmology, and is a leading cause of visual loss in the developed world. While new advances such as VEGF inhibitors are a breakthrough in treatment, current evidence demonstrates that a substantial number of patients with DME do not respond fully. I believe KalVista's approach, targeting a novel non-VEGF pathway, could represent a further important step in treating this condition."

Graham Boulnois of SV Life Sciences and Chairman of KalVista's board of directors, said: "The exciting discoveries regarding plasma kallikrein inhibition and its potential as a new approach to treating DME have created a significant opportunity. We believe that in KalVista we have put in place all the necessary scientific, clinical and drug discovery and development expertise, and sufficient funding, to capitalize on this opportunity and create a highly differentiated and valuable company."

Andrew Crockett, KalVista's CEO, said: "I am delighted that KalVista has garnered substantial financial support from leading life sciences investors Novo A/S and SV Life Sciences to fund this exciting new business. We have an ambitious target to become a leading company focused on the development of novel treatments for DME and believe we have the team, the expertise, the assets and the approach to achieve this goal."

KalVista is a new ophthalmology company with a focus on diabetic macular edema (DME). KalVista is developing novel plasma kallikrein inhibitors, which represents a new approach to the treatment of DME, a leading cause of adult visual loss in developed countries. KalVista has an advanced pre-clinical product pipeline and is targeting both intravitreal injection and oral administration. Although VEGF inhibitors clearly can benefit DME, a significant number of patients do not respond fully to these agents and have limited treatment options. Plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option.

KalVista's founders include world-leading experts in diabetic retinopathy, Dr Lloyd Paul Aiello, Professor of Ophthalmology at Harvard Medical School and Director of the Joslin's Beetham Eye Institute, and Dr Edward Feener, Associate Professor of Medicine at Harvard Medical School and Joslin Diabetes Center. In addition to this therapeutic expertise, KalVista has a management team with proven experience in bringing small molecules through the clinic to commercialisation and as a result has attracted significant financial backing from leading life science investors, SV Life Sciences and Novo Ventures.

http://www.kalvista.com

What is Stiff-Person Syndrome?

August 26th, 2011

One very rare and unusual condition associated with diabetes is Stiff-Person syndrome, also referred to as Myotonic Dystrophy. Stiff-Person syndrome (SPS) is a central nervous system disorder characterized by severe muscle stiffness that moves from place to place in the trunk, arms and legs. SPS affects about 1 in 1 million Americans, and about 1 in 10,000 diabetics.

Someone with SPS is exceedingly hypersensitive to normal stimuli such as sound, touch and emotional stress. A sudden noise, tap or worry can trigger muscle spasms that distort the body into hunched over stiff postures. People with SPS suffer from frequent falls when spasms are triggered by commonplace noises like a door slamming or a car horn. Because people with SPS lack normal protective reflexes, spasms and falls can result in serious injuries, including fractures, muscle tears and joint dislocations.

SPS is also referred to as "Stiff Man Syndrome", although - like many autoimmune conditions - it is much more common in women than in men. SPS usually strikes between the ages of 30 and 50, but the syndrome can also occur as Stiff Baby Syndrome in children under three. Commonly, SPS begins with an exaggerated upright posture due to muscle stiffness in the lower back, and then moves into the legs. As the disease progresses the patient must move very slowly, as rapid movements can trigger severe spasms.

The unusual and unfortunate symptoms of SPS can be confused with those of fibromyalgia, Parkinson's disease or multiple sclerosis. Sufferers may also be misdiagnosed as having an anxiety or psychosomatic disorder. A diagnosis of SPS is aided by the detection of elevated levels of the antibody glutamic acid decarboxylase (GAD), which is present in the cerebral spinal fluid of about 80% of SPS cases.

GAD antibodies tests are also an important diagnosis tool for diabetes mellitus. GAD tests are used to differentiate between types of diabetes, to predict the risk and track the progression of the disease, and to predict the need for insulin therapy in type 2 diabetics. GAD reduces the brain's main inhibitory transmitter, GABA. It's theorized that this reduction of GABA interferes with the modulation of spinal cord reflexes, resulting in the hyperactivity and hyperexcitabity that characterizes SPS.

SPS can be treated, but not cured. Symptoms can be eased with a combination of anti-anxiety medications, anti-convulsants, muscle relaxers and pain medication. A recent study proved intravenous immunoglobulin treatment (a therapy for autoimmune diseases and immune deficiencies) effective in reducing stiffness and hypersensitivity in patients with Stiff-Person syndrome. Another study using the arthritis drug rituximab led to disappointing results.

The cause of SPS remains a mystery, but it appears to be an out of kilter autoimmune response in the brain and spinal cord. SPS is associated with other autoimmune diseases such as diabetes, pernicious anemia, thyroiditis, and the skin disease vitiligo. The National Institute of Neurological Disorders and Stroke is continuing to both conduct and support research into SPS, focusing on uncovering the cause of this rare and curious condition.

Crippling Condition Associated With Diabetes Often Misdiagnosed

September 2nd, 2011

A new article explains symptoms and treatments for Charcot foot, a form of localized osteoporosis linked to diabetes that causes the bones to soften and break, often resulting in amputation.

"Even though it was first described in 1883, the diagnosis and successful treatment of Charcot foot continue to be a challenge because this syndrome is not widely known or understood by the broader medical profession," said Lee C. Rogers, D.P.M., co-director of the Amputation Prevent Center at Valley Presbyterian Hospital in Van Nuys, CA.

"Charcot foot is now considered to be an inflammatory syndrome most often seen in patients with diabetes which can be successfully treated in its early stages." To read the full article on this little known diabetes complication on ScienceDaily and to view a picture of this crippling condition, CLICK HERE.

Maggot Therapy for Diabetic Ulcers

September 28th, 2011

diabetic ulcer

One of the complications of diabetes can be ulcerated wounds that won't heal, particularly on the feet. This is because diabetes causes nerve damage and impairs blood flow and circulation to the extremities. About 1 in 5 diabetics who seek hospital treatment do so because of foot problems, and diabetes is one of the leading causes of lower limb amputations worldwide.

The medical removal of dead or infected tissue from wounds such as diabetic ulcers is called debridement. Doctors typically use scalpels, high pressure fluid, or tissue-dissolving enzymes for the procedure. A less known procedure is maggot debridement therapy, or MDT.

MDT is also referred to as maggot therapy, or by the slightly less disturbing term "larva therapy". The therapy employs the use of live maggots (fly larvae hatched from eggs). These are no ordinary maggots, but FDA-approved, medical grade, phaenicia sericata (blow fly) larvae, available only by prescription.

Medical grade maggots do not feed on or bury into healthy tissue, but dissolve and consume only dead and diseased tissue. They also fight infection by killing bacteria. The maggots are so small when applied that they can not even be felt within the wound, although some patients feel pain when the maggots become bigger (after 24 to 36 hours). Once the maggots are removed, the pain ceases.

According to the Wound Care Information Network: "Maggots do not bite. They do not have teeth. They do have modified mandibles though, called mouthhooks, and they have some rough bumps around their body which scratch and poke the dead tissue, one of the mechanisms that debrides the wound. It is similar to a surgeon's rasper, but on a microscopic scale."

The maggots are held in place over the wound with a mesh-like bandage that allows air in and the wound to drain. Once the maggots have fed, they are ready to leave the wound, and many will bury themselves in the dressing for easy removal. Others can be wiped off with a damp piece of gauze. Any "stragglers" will leave the wound and burry themselves in a fresh bandage within 24 hours.

The use of maggots in medicine began centuries ago, when military doctors noticed that soldiers whose wounds had become infected with maggots healed better. During the 1920s, Dr. William Baer refined the use of medicinal maggots, selecting certain species that fed only on dead tissue, which he raised in the laboratory and used to treat soft tissue infections in children.

MGT became widespread in the 1930s, but fell out of favor in the 1940s with the advent of new antibiotics and improved surgical techniques. In 1989, clinical studies determined that maggot therapy was a safe and effective treatment, and it was recommended not as a therapy of last resort, but as a second or third line of treatment for non-healing wounds. Today, thousands of physicians from over 20 countries are routinely employing maggot therapy. Maggot therapy has been successfully used on wounds infected with the antibiotic resistant MRSA "superbug".

Many argue that no one wants live maggots in and on their body. The Wound Care Information Network retorts: "What patients do not want is a stinking, draining wound. What patients do not want is to lose their foot. What patients do not want is 4 more weeks of a treatment in which they do not see any benefit. To someone with a non-healing wound, wearing "baby flies" for 2 days is not too high a price to pay, if the potential for success is what is reported with MDT."

To read more about maggot therapy for diabetic ulcers on the Wound Care Information Network website, Click Here.

Healthy BMI does not mean Immunity from Diabetes

February 12th, 2014

Diseases and measures tend to have trends these days. People tend to check themselves with measures and other indices to check if they are at risk of an infection or a disorder or a disease. Earlier people were weight conscious and tended to fast and starve till they became a stick.

Now it is all about BMI

BMI or Body Mass Index is a measure by which one can check if the weight distribution in the body is correct. So depending on where the fat rests, one could tell if they suffer from any disease or would be prone to it.

Obesity is definitely a factor but not the only one

An obese person is an overweight person. This person would have accumulated a lot of fat leading to problems like blocked arteries, veins and other such problems. Both types of diabetes tend to make the body lose weight. With type I, the muscles simply lose their detection to allow sugar to accumulate in them. So, they would not allow the person to gain weight. This person would have weight loss and a slim frame. The person still has problems of diabetes. Is it not?

One should see where the fat is distributed

As such, a person with a thin frame but a pot belly could be the perfect example for a person with a not so good health. When fat accumulates in the legs or the arms, it is not considered to be harmful. The fat that accumulates in the heart or the liver or the kidney tends to cause the harm.

This fat could slowly accumulate, leading to swelling of the organs and blocking proper blood flow and hence progressive degeneration of the organ due to lack of oxygen availability.

The pancreas is a typical example

Whenever the fat accumulates on an organ, it tends to lose the flexibility and functionality. The pancreas has a lock like system which detects glucose and produces insulin. This insulin breaks down the glucose.

Imagine what will happen if the lock system fails? Of course the pancreas will lose its ability to produce insulin properly. This would lead to increased sugar levels and hence other complications which lead to diabetes type II.

Similarly think of what will happen to the lungs, heart and the kidneys? What if they all fail to do their work and not serve their purpose? The entire system and body will collapse and lead to undesired consequences.

So, a BMI alone does not indicate it all

From this, we can see that the BMI cannot be indicative of absence of any problem. The weight might be ideal to the height but, if there is fat in the abdomen and other areas like the heart or other places, then one could face problems of diabetes and other disorders.

As such, it would be great to follow a good lifestyle, healthy eating habits and exercise regularly. One need not worry much about new trends in indices and indications.